- Home
- CRSP vs NJR Comparison
CRSP vs NJR Comparison
Compare CRSP & NJR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- NJR
- Stock Information
- Founded
- CRSP 2013
- NJR 1922
- Country
- CRSP Switzerland
- NJR United States
- Employees
- CRSP N/A
- NJR N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- NJR Oil/Gas Transmission
- Sector
- CRSP Health Care
- NJR Utilities
- Exchange
- CRSP Nasdaq
- NJR Nasdaq
- Market Cap
- CRSP 4.9B
- NJR 4.6B
- IPO Year
- CRSP 2016
- NJR N/A
- Fundamental
- Price
- CRSP $51.83
- NJR $47.28
- Analyst Decision
- CRSP Buy
- NJR Hold
- Analyst Count
- CRSP 16
- NJR 6
- Target Price
- CRSP $72.27
- NJR $51.50
- AVG Volume (30 Days)
- CRSP 2.5M
- NJR 615.7K
- Earning Date
- CRSP 08-04-2025
- NJR 08-04-2025
- Dividend Yield
- CRSP N/A
- NJR 3.81%
- EPS Growth
- CRSP N/A
- NJR 72.02
- EPS
- CRSP N/A
- NJR 4.10
- Revenue
- CRSP $38,050,000.00
- NJR $2,096,114,000.00
- Revenue This Year
- CRSP $11.17
- NJR $9.27
- Revenue Next Year
- CRSP $296.09
- NJR $2.24
- P/E Ratio
- CRSP N/A
- NJR $11.53
- Revenue Growth
- CRSP N/A
- NJR 21.02
- 52 Week Low
- CRSP $30.04
- NJR $43.80
- 52 Week High
- CRSP $71.13
- NJR $51.95
- Technical
- Relative Strength Index (RSI)
- CRSP 40.26
- NJR 54.59
- Support Level
- CRSP $51.80
- NJR $46.54
- Resistance Level
- CRSP $55.30
- NJR $47.49
- Average True Range (ATR)
- CRSP 2.23
- NJR 0.66
- MACD
- CRSP -0.58
- NJR -0.03
- Stochastic Oscillator
- CRSP 4.66
- NJR 59.67
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About NJR NewJersey Resources Corporation
New Jersey Resources is an energy services holding company with regulated and nonregulated operations. Its regulated utility, New Jersey Natural Gas, delivers natural gas to nearly 600,000 customers in the state. NJR's nonregulated businesses include investments in commercial solar projects and several large midstream natural gas projects.